Literature DB >> 25036015

Use of 18F-FDG PET/CT imaging for evaluation of patients with primary splenic lymphoma.

Sellam Karunanithi1, Punit Sharma, Shambo Guha Roy, Beth Vettiyil, Atul Sharma, Sanjay Thulkar, Chandrasekhar Bal, Rakesh Kumar.   

Abstract

UNLABELLED: Primary splenic lymphoma (PSL) is a rare disease, and its management differs from other splenic malignancies. The purpose of the present study was to evaluate the role of 18F-FDG PET/CT in patients with PSL.
METHODS: We retrospectively evaluated the data of 17 patients with PSL (median age, 46 years; range, 3-64) who had undergone 50 18F-FDG PET/CT studies. Of the 50 PET/CTs, 15 were done for primary diagnosis/staging and 35 were done for restaging. PET/CT images were evaluated both qualitatively and quantitatively [maximum standardized uptake value (SUVmax)]. Combination of clinical/imaging follow-up and/or histopathologic diagnosis was taken as reference standard.
RESULTS: Of the total 50 F-FDG PET/CT studies, 27 studies (54%) were positive and 23 (46%) were negative for disease. PET/CT was true positive in 25 studies, true negative in 22 studies, false positive in 2 studies, and false negative in 1 study. Overall, per study-based sensitivity was 96.2%, specificity was 91.7%, and accuracy was 94%. In those studies performed for diagnosis/staging (15/50), PET/CT was true positive in all 15, with an accuracy of 100%. In those studies performed for restaging (35/50), sensitivity was 90.9%, specificity was 91.7%, and accuracy was 91.4%. No significant difference was seen in the accuracy of PET/CT between staging and restaging groups (P=0.601). On 18F-FDG PET/CT, splenic involvement was seen in 24 studies, lymph nodal involvement in 5 studies, liver involvement in 3 studies, and bone marrow involvement in 1 study. More than one site of disease was seen in 9 PET/CT studies. On semiquantitative analysis, the overall mean splenic lesion SUVmax was 6.9±7.9 (median, 4.6; range, 1.3-29). The mean value of ratio of SUVmax of splenic lesions and SUVliver was 4.4±5.5 (median, 2.4; range, 0.9-24.2). On comparison of areas under the curve, the mean value of ratio of SUVmax of splenic lesions and SUVliver was found to be superior to SUVmax alone for this differentiation of involvement from normal spleen (P=0.018).
CONCLUSION: 18F-FDG PET/CT seems useful in patients with primary splenic lymphoma and shows high diagnostic accuracy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25036015     DOI: 10.1097/RLU.0000000000000523

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  6 in total

1.  Lymphoma Causing Gastrosplenic Fistula Revealed by FDG PET/CT.

Authors:  Trent P Wang; Mohan Doss; Jeffrey L Tokar; Sanjay Reddy; Stefan K Barta; Jian Q Yu
Journal:  Clin Nucl Med       Date:  2017-11       Impact factor: 7.794

2.  FDG-PET imaging to detect and characterize underlying causes of fever of unknown origin: an unavoidable path for the foreseeable future.

Authors:  Abdullah Al-Zaghal; William Y Raynor; Siavash Mehdizadeh Seraj; Thomas J Werner; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01       Impact factor: 9.236

3.  Fever of unknown origin revealed to be primary splenic lymphoma: A rare case report with review of the literature.

Authors:  Pan-Ge Sun; Bei Cheng; Jin-Feng Wang; Ping He
Journal:  Mol Clin Oncol       Date:  2016-12-14

Review 4.  Imaging patterns in non-traumatic spleen lesions in adults-a review.

Authors:  Matthew Tan; Hsien Min Low; Vishalkumar Shelat; Cher Heng Tan
Journal:  Jpn J Radiol       Date:  2022-01-31       Impact factor: 2.374

5.  Is there a reliable size cut-off for splenic involvement in lymphoma? A [18F]FDG-PET controlled study.

Authors:  Dominik Berzaczy; Alexander R Haug; Markus Raderer; Barbara Kiesewetter; Gundula Berzaczy; Michael Weber; Marius E Mayerhoefer
Journal:  PLoS One       Date:  2019-03-08       Impact factor: 3.240

6.  Functional Parameters of 18F-FDG PET/CT in Patients with Primary Testicular Diffuse Large B-Cell Lymphoma.

Authors:  Jing Yang; Sha Zhu; Fuwen Pang; Miao Xu; Yiting Dong; Jianqi Hao; Xuelei Ma
Journal:  Contrast Media Mol Imaging       Date:  2018-09-27       Impact factor: 3.161

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.